SynthesisFrontiers in pharmacology2025
Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction-associated fatty liver disease (MAFLD): a Bayesian network meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the relative efficacy of dietary supplements and pharmacological agents in improving metabolic and oxidative stress outcomes in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) through a systematic review and Bayesian network meta-analysis. Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched to identify randomized controlled trials (RCTs) published between 1 January 2014, and 3 March 2024, that evaluated the effects of dietary supplements or pharmacological agents on MAFLD. Results: A total of 106 RCTs involving 7,273 participants were included, involving a variety of nutritional and pharmacological interventions. Pharmacological intervention plus bioactive regulator was the most effective in reducing triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C). Nutrient plus pharmacological intervention was the most efficacious in improving glycated hemoglobin (HbA1c) and insulin levels. Pharmacological intervention plus another pharmacological intervention was most effective in reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Phytochemicals significantly reduced interleukin-6 (IL-6), while bioactive metabolic regulators markedly decreased tumor necrosis factor-α (TNF-α). Herbal extracts demonstrated superior effects in enhancing total antioxidant capacity (TAC) and superoxide dismutase (SOD), while oleoylethanolamide (OEA) improved antioxidant enzyme activity and reduced malondialdehyde (MDA) levels. Further analysis revealed that garlic exerted the strongest effect in improving overall antioxidant capacity, whereas L-carnitine showed the most significant efficacy in suppressing lipid peroxidation. Conclusion: Multicomponent or mechanistically complementary interventions exhibited more stable potential benefits in improving glucose and lipid metabolism. Bioactive metabolic regulators (L-carnitine), endogenous lipid regulators (OEA), and herbal extracts (garlic) all demonstrated strong efficacy in enhancing antioxidant defense and alleviating oxidative damage. Further high-quality RCTs are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024555065.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.